Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alexandre Nguimfack1, Eudoxia Filipe2, Dercio Filimao3

  • 1Division of Global HIV & TB, US Centers for Disease Control and Prevention, Maputo, Mozambique.

Revista Mocambicana De Ciencias De Saude
|February 25, 2025
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CNR1 and CNR2 Cannabinoid Receptor Mutations in Cancer Cells.

Current issues in molecular biology·2026
Same author

Tuberculosis after TB Preventive Therapy in Persons Living with HIV Recently Initiating Antiretroviral Therapy, Mozambique.

Emerging infectious diseases·2026
Same author

Hospitalization Free-Survival, Adverse Drug Reactions, and Retention in Care Outcomes of an Outpatient Treatment Model for Cryptococcal Meningitis in PLWH in Maputo, Mozambique.

Tropical medicine and infectious disease·2026
Same author

Prevalence and determinants of being out-of-care among HIV-positive young people aged 15-24 years in Mozambique: findings from the 2021 population-based HIV impact assessment survey.

BMC infectious diseases·2026
Same author

HIV incidence and prevalence among adults in Mozambique: estimates from the Population-based HIV Impact Assessment Survey (INSIDA 2021) and district-level modelling.

Journal of the International AIDS Society·2025
Same author

Dolutegravir Resistance in Mozambique: Insights from a Programmatic HIV Resistance Testing Intervention in a Highly Antiretroviral Therapy-Experienced Cohort.

Infectious disease reports·2025

Advanced HIV Disease (AHD) diagnosis remains a challenge in Mozambique. Low CD4 testing coverage hinders early identification and treatment, impacting progress toward HIV elimination goals.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Epidemiology

Context:

  • Advanced HIV Disease (AHD) presents a significant barrier to achieving the UNAIDS 95-95-95 targets in Mozambique.
  • Understanding AHD prevalence and patient demographics is crucial for effective intervention strategies.

Purpose:

  • To assess the prevalence of Advanced HIV Disease (AHD) among individuals initiating or re-initiating antiretroviral therapy in Mozambique.
  • To evaluate the coverage of CD4 testing in eligible patients within the national AHD diagnosis and treatment program.

Summary:

  • A review of data from October to December 2023 across 79 Mozambican health facilities revealed that only 36% of eligible individuals received a CD4 test.
  • Of those tested, 25% were diagnosed with AHD, predominantly among newly initiated patients.
Keywords:
Advanced HIV DiseaseCD4HIVPEPFARPVHIV

Related Experiment Videos

  • The study highlights low CD4 testing coverage as a critical obstacle.

    • Impact:

    • Low CD4 testing rates impede the early detection of AHD, contributing to higher mortality rates.
    • Addressing these testing gaps is essential for reducing mortality and advancing Mozambique's HIV elimination efforts.
    • Improved AHD identification is vital for achieving national and global HIV control targets.